Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Key Inclusion Criteria: * Willing and able to provide written informed consent or for those individuals where hepatic encephalopathy affects their ability to provide initial or ongoing consent, has an appropriate and legally-authorized representative (LAR) willing and able to provide consent on behalf of the individual. * HCV RNA infection with quantifiable virus at screening * Must have chronic genotype 1 or 4 HCV infection for ≥ 6 months by medical history or liver biopsy * Currently on the liver transplantation wait list * Screening electrocardiogram (ECG) without clinically significant abnormalities. * A negative serum pregnancy test result is required for females Key Exclusion Criteria: * Any previous solid organ transplant * Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with participant's treatment, assessment, or compliance * HIV infection or a positive hepatitis B virus surface antigen result * History of malignancy (with exception of hepatocellular carcinoma within Milan criteria, certain resolved skin cancers or other early cancer for which surgical resection is considered to be completely curative) * Treatment with any approved or experimental medication with known anti-HCV activity within 1 month prior to screening date * Prior exposure to an HCV non-structural protein (NS)5A inhibitor * Patients on hemodialysis prior to or at the time of transplantation will be excluded * Creatinine clearance (CLcr) \< 40 mL/min at screening or \< 40 mL/min on day of transplant * Participation in a clinical study with an investigational drug or biologic within 28 days prior to screening visit * Receipt or planned receipt of an organ from an HCV positive donor Note: Other protocol defined Inclusion/Exclusion criteria may apply.